Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279710 | 0.77 | RIPK1 (0.43) | ROCK2OPRK1SCN1ASCN8ACYP3A4 | |
| SCHEMBL274317 | 0.77 | RIPK1 (0.43) | ROCK2OPRK1SCN1ASCN8ACYP3A4 | |
| SCHEMBL12350663 | 0.75 | ACHE (0.48) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL4222919 | 0.72 | SCN1A (0.58) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL4227169 | 0.72 | SCN1A (0.58) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL4218837 | 0.71 | SCN8A (0.60) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL4220874 | 0.71 | SCN8A (0.60) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL331018 | 0.71 | BCHE (0.68) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL331017 | 0.71 | BCHE (0.68) | ROCK2BCHEACHEBACE1OPRK1 | |
| SCHEMBL4227789 | 0.70 | SCN1A (0.50) | ROCK2BCHEACHEBACE1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
| WO-2008138843-A1 | IMIDAZOPYRIDINES AND TRIAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT OF JOINT DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | NOD1, TNF, NOD2 | ROCK2 4200/4885BCHE 3961/4885ACHE 3930/4885 |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | RRP15, RARS2, RO60 | ROCK2 1074/4885BCHE 1756/4885ACHE 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.